| ACCESS ASIA BD Forum @JPM 2026

From its inception in 2004, Medicilon (SHA: 688202) has been committed to providing comprehensive research and development (R&D) services to biopharmaceutical companies, research institutions, and other organizations working in the preclinical space, with the primary objective of supporting and accelerating pharmaceutical, bio-pharmaceutical and medical device R&D worldwide.

- Chemistry
- Biology
- Early DMPK

- API/Formulation
- CMC Research

- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Drug Safety Evaluation
- Bioanalysis

- FDA
- NMPA
- EMA
- TGA
- MFDS
- PMDA



marketing@medicilon.com www.medicilon.com
20 Maguire Road, Suite 103, Lexington, MA 02421, USA
585 Chuanda Road, Pudong, Shanghai, 201299, China

15-PGDH inhibitor

Zhang et al. Science 2015;

Lead Program - HW201877

A potenəl·ƭ Ŭǌst in cƭl·ăă ƨǌl·ƭ therapy for ɪŋbammatory boweƭ ŘɪăŜl·ăŜ (IBD)







ABX464/Obefazimod is a phase 3 best-in-disease (miRNA modi) o al d ug candidate fo IBD developed by Abivax

MRGPRX2 antagonist



Lead Program - HW281171

! y2ØŜt ămI·tt m2tŜcdztŜ 2NJI·t ŘNJdzƎ for chronic spontaneous dzNJəcaria (CSU)

- *in vivo*



Contact: David Wang, wangdaoyi@renfu.com.cn

P2X3 Receptor Inhibitor



Ref nce:
Guo et al. Nat Commun 14, 5844 (2023)
Zhang et al. Pu in gic Signal. 2022 Sep;18(3):289-305.
Zang et al. Eu J Med Chem. 2025:300(118116)

Lead Program – HW091077

A potenəl·f best-in-ŏfl·ăă 2ℕl·f therapy for refractory chronic cough (RCC)

Compound	Gefap



Contact: Subo Liao, subo.liao@humanwellus.com





Contact: Yingfu Li, yingfuli@hyperwaypharma.com

BT-114143, a NoØŜf and Potent SmI·ff- a2fŜcdzfŜ tfI·ăY inogen !ŏəØI·ə2y Inhibitor for HyLJŜNŬōNJky2fysis





Ex vivo Efficacy of BT-114143 and TXA in Human Whole Blood TEG Analysis (n=6)

Analyte	Mean IC_{50} (☒M)	Mean IC_{90} (☒M)
BT-114143	0.56	1.01
TXA	3.39	10.12

Phase I Study of Safety, T2fŜrI·ōλtfλűy, Pharmacokineəŏă, and 9ĚLJt2NI·tory .λ2t23ΞλcI·t Eũects of Intravenous BT-114143 in HŜI·tűhy V2fdznteers

Phase IbΣ a dzfəŎŜnter, Randomized, Conű№2tted, Dose-EscI·fI·ə2y Study of BT-114143 Lyʔ̂Ŏə2yʹλyʹPI·əŜnts with !ōy2NYʹI·t Uterine .fŜeding (AUB)

×

Contact: Shaomei Zeng, shaomei.zeng@btyy.com

- Gluetacs Therapeutics is a biopharmaceutical company developing oral small-molecule targeted protein degraders.
- Seeking strategic partnerships for the development of its pipeline assets, including licensing, co-development, and/or collaborative opportunities.
- Headquarter: Shanghai, China

- A proprietary library of small-molecule degraders, including
  - Molecular glues and bifunctional degraders recruit target proteins to E3 ligases
  - Ubiquitination marks the target protein for recognition and selective degradation by the proteasome
  - Orally available small-molecule modality
  - Expands the druggable space
  - Novel scaffold design enables enhanced substrate selectivity and efficacy
  - Operates via catalytic "event-driven" pharmacology



- IKZF3/1 degrader
- Relapsed and Refractory Multiple Myeloma (r/r MM)
- Phase II Clinical Trials

- ✓ No DLTs were observed at all dose levels (0.5, 1, 2, 3, 4 and 5 mg).
- ✓ No TEAEs or TRAEs led to GT919 discontinuation, dose reduction or death.
- ✓ Wide safety dose range and promising safety profile.

- ✓ ORR of 50% among 10 evaluable triple-refractory patients that received GT919 at RP2D.



- IKZF3/1 degrader
- Relapsed and Refractory Multiple Myeloma (r/r MM)

21616

ATTR a eutic MOA[1] o



[1] Adapted from Ruberg FL et al. Transthyretin Amyloid Cardiom

CT06760455/CTR20244864

MEDICILON

MEIJI
Innovation for Better Life

Seƒ-emdzfăλfying Lipid Nanopl-ℕJəŎfe (SELNP) tfl-ùorm



Lead Program – MJC-001

MJC-001 demonstrates exceffent therapeuəŏ eŶŏacy in mufəLJfŜ PDX mouse s2fłŘ tumor modefă





YAFO

Contact: Huiyu Huang, huiyu.huang@meijibiopharm.com

			Fα						

An overview



Leading drug candidate

- **Rab-001: First-in-Ôtl·ää drug for osteonecrosis in humans**

Dtdzcocℕə0Ƶ⅄R-induced osteoporosis and osteonecrosis in mouse



Primary osteoporosis f2tt2ø⅄y∃ Ŝstrogen ŘŜŬciency



Fracture hel·ting

Rab-001 has excŜtfŜnt safety and PK LJN2ŬtŜă in ctinicl·t studies	Phase I a & b Studies

- **Rab-001d: Potenəl·t to be the disease-modifying drug for OA**





Contact: JIWEI CHEN, jiwei@rabpharma.com

- Headquarters: Wuhan, China
- Committed to the discovery and development of antibody-based therapies (BsAb, ADC, BsAb-ADC, etc.) for the treatment of oncology and autoimmune diseases.
- Seeking for partnership for clinical development (licensing, co-development and/or collaboration) of multiple bispecific antibodies and ADCs in our pipeline.

VersatiBody Platform

Engineer and modify the structure of naturally occurring antibodies to optimize their function and binding affinity

Distinct antibody structures and modality tailored for each specific disease, such strong adaptability enables the development of antibodies against a wide range of targets

HanXbio *VersatiBody*

Incorporate modular design for the rapid assembly of new antibody constructs and easy antibody production and development

- Target selection based on disease biology
- Molecular design per MoAs
- Manufacturability and stability validation



Note: illustrative purposes only.

Lead ADC Program – HX111

- HX111: a “FIC” ADC targeting OX40
- selected types of T-cell or B-cell lymphoma as well as certain types of solid tumors
-
  - A “FIC” OX40-ADC with dual-modalities: 1). ADC-based robust and durable anti-tumor effects on selected types of lymphoma (most PTCL) and solid tumors; 2). Immunotherapy for pan-solid tumors featured with potent Treg-depleting activities.
-
  - Over-expressed in selected lymphoma and leukemia (L/L), including nearly all ATLL, AITL, NK/T, Histiocytic lymphoma, and some EBV+ DLBCLs, etc.
  - Also expressed in significant portion of solid tumors, e.g. selected types of H&NSCC, breast, cervical cancer
  - Little expression among normal tissues, including normal lymphocytes, with potentially minimal “off-target” toxicities.
-
  - Potent efficacy in multiple OX40+ mouse models.
  - Confirmed potent Treg-depletion activities, enabling its anti-tumor immunity.
  - Similar spectrum of toxicities as other MMAE based ADC in cyno-monkeys, enabling easy toxicity management in clinical trials.
-
  - IND approved
  - FIH (Phase 1a/1b) in early 1Q 2026 (multi-center)
  - Combination options with other immunotherapies

HX111 is highly active in OX40+ tumors (ADC MoA)











HX111 is also active in OX40- tumor model (Treg-depletion MoA)



Contact: Sabrina Wu, sabrina.wu@waterstonepharma.com

NLRP3 as a Therapeutic Target



Lead Program – ZL-65

ZL-65 Shows Neuroprotective Effects in SNpc of 6-OHDA PD Rat Brain



Sham (control)

Brain



Levodopa
15 mg/kg



ZL-65
100 mg/kg

Contact: Neil Wang, neilwang@zenitar.cn

Robust .ƛ2f2ƎƛǑă tƛLJefƛyŜ

Type	Project	Indication	Lead	Preclinical	IND	Phase1	Phase2	Phase3	Launch
Biosimilar	Pegfilgrastim	Oncology							
Biosimilar	Insulin Glargine	Diabetes							
Biosimilar	Rituximab	Oncology							
TCE	F182112 (BCMA-CD3)	Oncology, AID							
Fusion	F008 (rNIF-NHH)*	AIS							
Fusion	F012 (PEG-UHC)*	Gout, HUA							
TCE	LNF2007 (Claudin18.2-CD3)	Oncology							
mAb	LNF2102 (FGFR2b)	Oncology							
TCE	LNF1904 (CD19-CD3)	Oncology, AID							
Fusion	LNF2003 (GLP1/FGF21)	MASH							
Protein	LNF2401 (KLK1)	AIS							
ADC	LNF2105 (NECTIN4)	Oncology							

FDA IND Approval

FDA IND Approval

FDA IND Approval

*.F008 is Recombinant Neutrophil Inhibitory Factor and Hirulog Hybrid
F012 is PEG-Uricase of Human-Canine

SAFETY AND EFFICACY OF F182112 IN PATIENTS WITH RRMM



F182112 is 2+2 Symmetric Format
Without ADCC and CDC acəǾity

	F182112-001		MajesTEC-1 (Tecvayli)		MagnetisMM-3 (Elranatamab)	
	All grade	≥Grade 3	All grade	≥Grade 3	All grade	≥Grade 3
	no. of patients (%)					
Any adverse event(TEAE)	107 (99.70)	100 (92.59)	165 (100)	156 (94.5)	123 (100)	87 (70.7)
Hematologic (≥20%)						
Neutropenia	35 (31.08)	32 (29.6)	107 (64.8)	106 (64.2)	60 (48.8)	60 (48.8)
Anemia	68 (63.55)	26 (24.30)	86 (52.1)	61 (37.0)	60 (48.8)	46 (37.4)
Thrombocytopenia	62 (57.01)	24 (22.43)	66 (40.0)	25 (15.2)	23 (20.3)	18 (14.6)
Lymphopenia	50 (46.73)	42 (39.25)	92 (55.8)	84 (50.9)	80 (65.0)	81 (65.9)
Leukopenia	61 (56.36)	48 (44.86)	29 (17.6)	12 (7.3)		
Cytokine release syndrome	74 (69.16)	0	119 (72.1)	1 (0.6)	71 (57.7)	0
Neurotoxic event	1 (0.93)	0	24 (14.5)	1 (0.6)	4 (3.4)	0
Infections and infestations	81 (75.7)	46 (42.99)	126 (76.4)	74 (44.8)	86 (69.9)	49 (39.
Tumor Lysis Syndrome	1 (0.93)					



Contact: Zhenyu Li, lizhenyu@vip.lunan.cn

ZovagfdzəŘŜY An dztűNJ-f2yƎ I·ŏəyƎ GLP-1 RA with PK to support monűKty dosing



coli

We are seeking moəvated partners to co-devŜt2LJ & co-commerciatize tŜI·Ř program ZT002 in US + Europe

hNI·t /yŏfac PepəŘŜ



Lead Program – SG-6001





Innovation for Health

Tandem Expression of PEPəŘes (TE-PEP®) ttl·ùorm

Lead Program – PN20

Phase Ia PLT count, s‹yƎfŜ dose





Phase Ib in CIT paəents, repeated doses





Phase I /tŷycI·f HƗƎKtights

Phase Ib in CLDT paəents, s‹yƎfŜ dose

×

PfI·yŷŜŘ /tŷycI·t MifŜstones

Contact: Dr.Frank FAN, frank@pegbiocq.com


25
20
15
10
Infarction Area(%)
***
P=0.0001
6 mg/kg
Edaravone
5 mg/kg
10 mg/kg
15 mg/kg
DA414


100mg(N=8)
200mg(N=6)
planned time post-dose (hours)

- Migraine is a prevalent neurological disorder, which is characterized by recurrent, moderate to severe unilateral pulsatile headaches.
- Faster pain relief remains an unmet need for migraine patients.
- Calcitonin gene-related peptide (CGRP) and its receptor are clinical approved targets for pain alleviation.
- ZAVZPRET, the first and only CGRP receptor antagonist nasal spray with frequently adverse events- [% ZAVZPRET vs % placebo]



- PRT-064040 exhibited better inhibitory activity (blocking CGRP-CGRP receptor activation) and higher binding affinity with CGRP receptor than Zavegepant (ZAZPRET).



- The permeability enhancer in PRT-064040 formulation promoted a higher systemic exposure (AUC) and faster absorption (Tmax).



- PRT-064040 displayed more sustainable efficacy than Zavegepant in a Cynomolgus hCGRP-induced dermal blood model, even at lower dose (lower plasma exposure).

Drug	Clinic Study	Dose	Common Adverse Drug Reaction	
			Dysgeusia	Nasal discomfort
PRT-064040*	Health subjects SAD	Dose 1	0	0
		Dose 2	0	0
		Dose 3	0	0
		Dose 4	0	0
		Dose 5	0	0
0	0			Dose6
				Health
				Health
				Health
				[illegible]
			Zavegepant	
				[illegible]
				[illegible]

Derived from unpinged data.

- PRT-064040 was well-tolerated and no dysgeusia reported in a completed Phase I study [NCT07016516]. The safety and PK support clinical advancement [CTR20254825]

乐普医药
LEPU PHARMA



Syntheə̊ fethatity



Lead Program - YY2201





MEDICILON

ChemT

Bio-tech

In Biomanufacutring, increasing productivity without triggering stress, metabolic imbalance, or quality drift remains a major challenge. , our AI-driven Virtual Cell platform, addresses this by integrating multi-omics data with large-scale literature mining to identify high-value, druggable, and novel control points in cell biology.

models how cells respond to different nutrients, stresses, and perturbations, revealing levers that improve viable cell density, productivity, and metabolic stability. This enables gene target discovery and molecule design to act on the targets that deliver higher, more consistent, and scalable performance across manufacturing systems — keeping cells in an optimized productive state without changing production by a new cell line, cell line gene editing, or cell adaptation.



A Virtual Cell Platform For Target discovery and generation



Gene targets simulation outcome and prediction summary by CelMo

Knockout Type	Gene(s) Knocked Out	Predicted Effect	Likelihood Score	Shortlisted
Single Gene	Gene 1	BCAA, mTORC1, productivity	0.72	Yes
Single Gene	Gene 2	BCKA, redox efficiency	0.55	No
Single Gene	.....	BCAA import, mTORC1	0.43	No
Double Gene	Gene 1 + Gene 2	BCAA retention, productivity	0.84	Yes
Double Gene	.....	cytosolic BCAA, mixed effects	0.68	No

Wet lab validation on the gene target identified by CelMo (Gene 1 KO)









In vivo efficacy





Binding Prediction Accuracy

<1 kcal/mol error, 50% more accurate than traditional docking reducing wet-lab failure rates

Efficiency

>30% increase in generation efficiency

Target Identification

Accelerates and improves early-stage pipeline decisions; captures non-obvious targets

Interaction Modeling

Intelligently propose gene targets and simulate outcome with

preserving the key interactions required for efficacy

User Experience

Virtual screening of 100,000 molecules/day allowing rapid iteration and feedback in molecule optimization

YAFO

Contact: ling.wu@chemtbio.com; jie.sun@chemtbio.com

CD36 DerivaəØŜ PepəŘŜ ttl·ùorm

$CD36^{93-110}$

壹宸生物 Yi Chen Bio

Company Introducəon



Lead Programs







Contact: contact@yichen-bio.com

Mechanism:

Lead Program - RDc001

-
-
-

Lead Program – SBC003

-
-
-

百奥泰
BIO-THER



www.medi

marketing@medi com

20 Maguire Road, Suite 103, L ington, MA , USA